Ignite Creation Date:
2025-12-24 @ 12:46 PM
Ignite Modification Date:
2025-12-27 @ 10:40 PM
Study NCT ID:
NCT04449861
Status:
COMPLETED
Last Update Posted:
2024-11-27
First Post:
2020-05-06
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-12-07
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-30
Completion Date Type:
ACTUAL
First Submit Date:
2020-05-06
First Submit QC Date:
None
Study First Post Date:
2020-06-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-03-22
Results First Submit QC Date:
None
Results First Post Date:
2024-11-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-20
Last Update Post Date:
2024-11-27
Last Update Post Date Type:
ACTUAL